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The unbiased approach to predicting 
outcomes.™
Predictor 
PIPELINE
Situation
It is well known that health care costs are continuously on 
the rise and with new prescription products entering the 
market almost weekly, it can be difficult to contain both 
pharmacy and medical costs and remain within a budget. 
Decision makers are faced with the challenge of  
evaluating these new products and determining their place 
in therapy. UMass Medical School’s Clinical Pharmacy  
Services (UMass) seeks out opportunities to engage 
decision makers within the realm of health insurance 
and managed care in conversation regarding the specific 
challenges they currently face and to identify their areas 
of need. Most recently, these discussions have highlighted 
an interest in finding ways to determine the potential 
budget impact, on both the pharmacy and medical side, for 
drugs that have recently entered or are about to enter the 
market. 
Solution
In an effort to help meet this need, UMass has expanded 
into the field of economic modeling. By creating  
pharmacoeconomic comparisons, UMass is able to help 
decision makers proactively evaluate the potential impact 
of drugs that are in late stages of clinical development. 
These analytic models offer a comprehensive,  
customizable and unbiased supplement to the clinical 
information necessary to determine appropriate formulary 
placement. They provide information to support proactive 
formulary management of products that are expected to 
gain FDA approval as well as have a significant financial 
and clinical impact. 
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Results
One of the first models UMass created was a comparison 
of the investigational oral factor Xa inhibitor, rivaroxaban 
(Xarelto®), to enoxaparin. This model compares these 
agents for the prevention of venous thromboembolism 
after total hip replacement surgery. In order to gain  
feedback on the provision of this service, the model has 
been presented to various clinical experts within the  
University of Massachusetts clinical system as well as to 
our MassHealth and MedMetrics clients. 
 
Benefits of Pipeline PredictorRx™
 ◗ Unbiased approach to pharmacoeconomic  
comparisons
 ◗ Academic medical center clinical expertise
 ◗ Customizable modeling utilizing client specific data
 ◗ Continual evaluation of models as new drug data 
becomes available
 ◗ Proactive formulary management tool   
 
